check_circleStudy Completed
Breast cancer, Bone Metastases
Bayer Identifier:infoA unique number for a trial given by Bayer.
15468
ClinicalTrials.gov Identifier:infoA unique number for a trial given by United States government.
EudraCT Number:infoA unique reference for a trial given by European medical agency.
EU CT Number:infoA unique reference for a trial given by European medical agency under EU Clinical Trial Regulation
Not Available
BAY88-8223, Alpharadin, Breast Cancer pts with bone dominant
Trial purpose
The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.
Key Participants Requirements
Sex
FemaleAge
21 - N/ATrial summary
Enrollment Goal info
23The overall number of participants needed for a trial.
Trial Dates info
January 2010 - January 2012Trial dates are when the trial starts and ends. If they are in the future, then they are estimates and can change before or during a trial.
Phase info
Phase 2A phase is a step in the research of a new treatment.
Could I Receive a placebo info
NoA “placebo” looks like a treatment but usually does not have any real treatment. A placebo is used to make sure the effects of a treatment that are seen in a trial are actually caused by that treatment.
Products info
Xofigo (Radium-223 dichloride, BAY88-8223)A “product” can be any kind of drug, medical device, vaccine, or other treatment that is being studied in a trial.
Accepts Healthy Volunteer info
NoA healthy volunteer is a person who takes part in a trial but does not have a disease or condition. Usually, healthy volunteers are in Phase 1 trials.
Where to participate
Status | Institution | Location |
---|---|---|
Completed | Weston Park Hospital, Cancer Clinical Trials Centre, Academic Unit of Clinical Oncology | Sheffield, United Kingdom |
Completed | Institut Jules Bordet | Brussels, 1000, Belgium |
Completed | Oslo University Hosptial, The Radium Hospital | Oslo, 0310, Norway |
Completed | CHU du Sart Tilman | Liège, 4000, Belgium |
Primary OutcomeinfoA primary outcome is the most important effect of a treatment that is measured in a trial. Most trials have one primary outcome measure, but some have more than one.
- Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)date_rangeTime Frame:16 weeksenhanced_encryptionNoSafety Issue:
Secondary OutcomeinfoA secondary outcome is an effect of a treatment that is measured in a trial. A secondary outcome is less important than a primary outcome. But secondary outcomes are still important since they help researchers learn more about the effects of a treatment. Most clinical trials have more than one secondary outcome measure.
- All safety data, including adverse events, changes in laboratory variables, vitals signs, physical examination, late toxicitydate_rangeTime Frame:1 yearenhanced_encryptionYesSafety Issue:
- Biochemical markers (additional bone markers and CA15.3)date_rangeTime Frame:16 weeksenhanced_encryptionNoSafety Issue:
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)date_rangeTime Frame:1 yearenhanced_encryptionNoSafety Issue:
- Paindate_rangeTime Frame:1 yearenhanced_encryptionNoSafety Issue:
Trial design
Trial Type info
InterventionalDescribes the nature of the clinical study.
Intervention Type info
DrugAn intervention is a drug, medical device, vaccine, or other treatment that is being studied in a trial or is already approved for all patients to use. An intervention can also include treatments like changing diet and exercise, or educating people about a health topic.
Trial Purpose info
TreatmentThe main reason the clinical trial is being done.
Allocation info
Non-randomizedAllocation is the way treatments are assigned to the people in the trial.
Blinding info
Open Label“Blinding” means a person in a trial does not know what treatment they are using. Everyone in the trial knows which treatments they might get if they join the trial, but they do not always know which treatment they use during the trial.
Assignment info
Single Group AssignmentAn “assignment” is the way that people in a trial are assigned to use a treatment.
Trial Arms info
1A “trial arm” is a group of people in a trial. Each trial arm is assigned to use a specific treatment. Types of trial arms are: Experimental arm is a group assigned to use the treatment being studied in the trial Active comparator arm is a group assigned to use a treatment considered to be effective. The results of this group are compared to the results of the experimental arm. Placebo arm is a group assigned to use a placebo. A “placebo” looks like a treatment but usually does not have any real treatment. The results of this group are compared to the experimental arm. This helps make sure any effects that are seen in the experimental arm are actually caused by the main treatment being studied. No intervention arm is a group that is not assigned to use a treatment. The people in this group do not use any treatment during the trial.